TARSUS PHARMACEUTICALS INC (TARS) — insider trading
Health Care · NASDAQ
TARSUS PHARMACEUTICALS INC (TARS) has 59 reported SEC Form 4 insider transactions in our data, including 20 open-market sales among the most recent 59 (latest 2026-09-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | YARNO WENDY L | Director | Option exercise / conversion (derivative) | 302 | — | $0 | Form 4 |
| 2026-09-15 | YARNO WENDY L | Director | Option exercise / conversion | 302 | — | — | Form 4 |
| 2026-09-15 | PYOTT DAVID E I | Director | Option exercise / conversion (derivative) | 201 | — | $0 | Form 4 |
| 2026-09-15 | PYOTT DAVID E I | Director | Option exercise / conversion | 201 | — | — | Form 4 |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Option exercise / conversion (derivative) | 201 | — | $0 | Form 4 |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Open-market sale | 66 | $80.01 | $5.3K | Form 4 |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Open-market sale | 759 | $79.00 | $60.0K | Form 4 |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Open-market sale | 11,675 | $78.33 | $914.5K | Form 4 |
| 2026-09-15 | LINK WILLIAM J PHD | Director | Option exercise / conversion | 201 | — | — | Form 4 |
| 2026-09-04 | Neervannan Seshadri | Officer (Chief Operating Officer) | Open-market sale | 4,564 | $85.00 | $387.9K | Form 4 |
| 2026-09-04 | Lin Elizabeth Yeu | Officer (Chief Medical Officer) | Open-market sale | 1,590 | $90.00 | $143.1K | Form 4 |
| 2026-09-04 | Lin Elizabeth Yeu | Officer (Chief Medical Officer) | Open-market sale | 1,590 | $85.00 | $135.2K | Form 4 |
| 2026-09-04 | Lin Elizabeth Yeu | Officer (Chief Medical Officer) | Open-market sale | 5,386 | $90.00 | $484.7K | Form 4 |
| 2026-09-04 | Lin Elizabeth Yeu | Officer (Chief Medical Officer) | Open-market sale | 5,387 | $85.00 | $457.9K | Form 4 |
| 2026-09-04 | Azamian Bobak R. | Director, Officer (President/CEO and Board Chair) | Open-market sale | 2,900 | $91.27 | $264.7K | Form 4 |
| 2026-09-04 | Azamian Bobak R. | Director, Officer (President/CEO and Board Chair) | Open-market sale | 7,100 | $90.27 | $640.9K | Form 4 |
| 2026-09-02 | Lin Elizabeth Yeu | Officer (Chief Medical Officer) | Open-market sale | 1,590 | $80.00 | $127.2K | Form 4 |
| 2026-09-02 | Lin Elizabeth Yeu | Officer (Chief Medical Officer) | Open-market sale | 5,387 | $80.00 | $431.0K | Form 4 |
| 2026-09-02 | Azamian Bobak R. | Director, Officer (President/CEO and Board Chair) | Open-market sale | 10,000 | $80.06 | $800.6K | Form 4 |
| 2026-09-01 | Lin Elizabeth Yeu | Officer (Chief Medical Officer) | Open-market sale | 4,601 | $73.86 | $339.8K | Form 4 |
| 2026-06-25 | LINK WILLIAM J PHD | Director | Grant / award / vesting (derivative) | 806 | — | $0 | Form 4 |
| 2026-06-25 | LINK WILLIAM J PHD | Director | Grant / award / vesting (derivative) | 2,417 | — | $0 | Form 4 |
| 2026-06-25 | LINK WILLIAM J PHD | Director | Grant / award / vesting (derivative) | 3,837 | — | $0 | Form 4 |
| 2026-06-25 | PYOTT DAVID E I | Director | Grant / award / vesting (derivative) | 806 | — | $0 | Form 4 |
| 2026-06-25 | PYOTT DAVID E I | Director | Grant / award / vesting (derivative) | 2,417 | — | $0 | Form 4 |
| 2026-06-25 | PYOTT DAVID E I | Director | Grant / award / vesting (derivative) | 3,837 | — | $0 | Form 4 |
| 2026-06-25 | YARNO WENDY L | Director | Grant / award / vesting (derivative) | 1,209 | — | $0 | Form 4 |
| 2026-06-25 | YARNO WENDY L | Director | Grant / award / vesting (derivative) | 2,417 | — | $0 | Form 4 |
| 2026-06-25 | YARNO WENDY L | Director | Grant / award / vesting (derivative) | 3,837 | — | $0 | Form 4 |
| 2026-06-25 | CHAUDHURI BHASKAR | Director | Grant / award / vesting (derivative) | 2,417 | — | $0 | Form 4 |
| 2026-06-25 | CHAUDHURI BHASKAR | Director | Grant / award / vesting (derivative) | 3,837 | — | $0 | Form 4 |
| 2026-06-25 | Morrison Scott W | Director | Grant / award / vesting (derivative) | 2,417 | — | $0 | Form 4 |
| 2026-06-25 | Morrison Scott W | Director | Grant / award / vesting (derivative) | 3,837 | — | $0 | Form 4 |
| 2026-06-25 | Goldberg Andrew D. | Director | Grant / award / vesting (derivative) | 2,417 | — | $0 | Form 4 |
| 2026-06-25 | Goldberg Andrew D. | Director | Grant / award / vesting (derivative) | 3,837 | — | $0 | Form 4 |
| 2026-06-25 | Goodrich Katherine | Director | Grant / award / vesting (derivative) | 2,417 | — | $0 | Form 4 |
| 2026-06-25 | Goodrich Katherine | Director | Grant / award / vesting (derivative) | 3,837 | — | $0 | Form 4 |
| 2026-06-17 | Azamian Bobak R. | Director, Officer (President/CEO and Board Chair) | Open-market sale | 5,418 | $61.81 | $334.9K | Form 4 |
| 2026-06-17 | Azamian Bobak R. | Director, Officer (President/CEO and Board Chair) | Open-market sale | 4,582 | $61.24 | $280.6K | Form 4 |
| 2026-06-16 | Farrow Jeffrey S | Officer (See Remarks) | Open-market sale | 14,396 | $60.95 | $877.4K | Form 4 |
| 2026-06-15 | LINK WILLIAM J PHD | Director | Open-market sale | 1,928 | $62.94 | $121.3K | Form 4 |
| 2026-06-15 | LINK WILLIAM J PHD | Director | Open-market sale | 10,572 | $61.97 | $655.1K | Form 4 |
| 2026-06-15 | Goodrich Katherine | Director | Open-market sale | 2,954 | $62.08 | $183.4K | Form 4 |
| 2026-06-15 | Farrow Jeffrey S | Officer (See Remarks) | Option exercise / conversion (derivative) | 27,881 | — | $0 | Form 4 |
| 2026-06-15 | Farrow Jeffrey S | Officer (See Remarks) | Option exercise / conversion | 27,881 | — | — | Form 4 |
| 2026-06-12 | Goldberg Andrew D. | Director | Option exercise / conversion (derivative) | 2,954 | — | $0 | Form 4 |
| 2026-06-12 | Goldberg Andrew D. | Director | Option exercise / conversion | 2,954 | — | — | Form 4 |
| 2026-06-12 | YARNO WENDY L | Director | Option exercise / conversion (derivative) | 2,954 | — | $0 | Form 4 |
| 2026-06-12 | YARNO WENDY L | Director | Option exercise / conversion | 2,954 | — | — | Form 4 |
| 2026-06-12 | Goodrich Katherine | Director | Option exercise / conversion (derivative) | 2,954 | — | $0 | Form 4 |
| 2026-06-12 | Goodrich Katherine | Director | Option exercise / conversion | 2,954 | — | — | Form 4 |
| 2026-06-12 | CHAUDHURI BHASKAR | Director | Option exercise / conversion (derivative) | 2,954 | — | $0 | Form 4 |
| 2026-06-12 | CHAUDHURI BHASKAR | Director | Option exercise / conversion | 2,954 | — | — | Form 4 |
| 2026-06-12 | LINK WILLIAM J PHD | Director | Option exercise / conversion (derivative) | 2,954 | — | $0 | Form 4 |
| 2026-06-12 | LINK WILLIAM J PHD | Director | Option exercise / conversion | 2,954 | — | — | Form 4 |
| 2026-06-12 | Morrison Scott W | Director | Option exercise / conversion (derivative) | 2,954 | — | $0 | Form 4 |
| 2026-06-12 | Morrison Scott W | Director | Option exercise / conversion | 2,954 | — | — | Form 4 |
| 2026-04-24 | PYOTT DAVID E I | Director | Option exercise / conversion (derivative) | 1,383 | — | $0 | Form 4 |
| 2026-04-24 | PYOTT DAVID E I | Director | Option exercise / conversion | 1,383 | — | — | Form 4 |
Ask the chat about TARS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TARSUS PHARMACEUTICALS INC (TARS).
Last updated 2026-09-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.